RecruitingNCT06319378
25 mg or 1 mg psilocybin for depression linked to cancer
About this title
Read the official source — NCT06319378Researchers are comparing psilocybin 25 mg sod and psilocybin 1 mg sod to find out how the approaches affect depression symptoms in people with depression.
Medication studyAges 20–80Sweden
Understand this study
What is this study about?
Researchers are comparing psilocybin 25 mg sod and psilocybin 1 mg sod to find out how the approaches affect depression symptoms in people with depression.
Who could participate?
Listed age limits: 20 years to 80 years.
- Listed locations
- Gothenburg and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 19, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Section for Affective Disorders; Northern Stockholm Psychiatry
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Sweden
- Age range
- From 20 Years to 80 Years
- Official registry ID
- NCT06319378
- Official title
Show the full official title
CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Gothenburg · Stockholm · Uppsala
1 more locations
- Örebro
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing psilocybin 25 mg sod and psilocybin 1 mg sod to find out how the approaches affect depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Section for Affective Disorders; Northern Stockholm Psychiatry.
Does this study involve medication?
Yes. The study involves medication, including psilocybin 25 mg sod and psilocybin 1 mg sod.
Who can participate?
Listed age limits: 20 years to 80 years.
Is this study still recruiting?
The registry lists this study as recruiting.
